Tozinameran

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Nucleic Acid Created by `admin` on `Sat Dec 16 16:16:27 UTC 2023` Edited by `admin` on `Sat Dec 16 16:16:27 UTC 2023`
Nucleic Acid Type	mRNA VACCINE
Nucleic Acid Subtype	TRANSGENE
Sequence Origin	VIRAL
Sequence Type	COMPLETE
Record UNII	5085ZFP6SJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RNA INGREDIENT BNT-162B2

Preferred Name

English

BNT162B2

Preferred Name

English

BNT-162B2

Preferred Name

English

Tozinameran

Official Name

English

Tozinameran [WHO-DD]

Common Name

English

TOZINAMERAN [JAN]

Common Name

English

RNA (RECOMBINANT 5'-(1,2-((3'-O-METHYL)M7G-(5'->5')-PPP-AM))-CAPPED ALL URIDINE->N1-METHYLPSEUDOURIDINE-SUBSTITUTED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SECRETORY SIGNAL PEPTIDE CONTG. SPIKE GLYCOPROTEIN S1S2-SPECIFYING PLUS 5'-AND 3'-UNTRANSL

Common Name

English

PFIZER COVID-19 VACCINE

Common Name

English

COMIRNATY MRNA

Brand Name

English

tozinameran [INN]

Common Name

English

Code System Code Type Description

SMS_ID

300000019018

Created by admin on Sat Dec 16 16:16:28 UTC 2023 , Edited by admin on Sat Dec 16 16:16:28 UTC 2023

PRIMARY

INN

11889

Created by admin on Sat Dec 16 16:16:28 UTC 2023 , Edited by admin on Sat Dec 16 16:16:28 UTC 2023

PRIMARY

FDA UNII

5085ZFP6SJ

Created by admin on Sat Dec 16 16:16:28 UTC 2023 , Edited by admin on Sat Dec 16 16:16:28 UTC 2023

PRIMARY

NCI_THESAURUS

C173055

Created by admin on Sat Dec 16 16:16:28 UTC 2023 , Edited by admin on Sat Dec 16 16:16:28 UTC 2023

PRIMARY

CAS

2417899-77-3

Created by admin on Sat Dec 16 16:16:28 UTC 2023 , Edited by admin on Sat Dec 16 16:16:28 UTC 2023

PRIMARY

DAILYMED

5085ZFP6SJ

Created by admin on Sat Dec 16 16:16:28 UTC 2023 , Edited by admin on Sat Dec 16 16:16:28 UTC 2023

PRIMARY

WIKIPEDIA

Pfizer–BioNTech COVID-19 vaccine

Created by admin on Sat Dec 16 16:16:28 UTC 2023 , Edited by admin on Sat Dec 16 16:16:28 UTC 2023

PRIMARY

Sugar	Site Range	Site Count
D-Ribose (RNA)	1_2-1_4283	4282 / 4283
2'-O-Methyl-Ribose	1_1	1 / 4283

Linkage	Site Range	Site Count
Phosphate	1_2-1_4283	4282 / 4282

Related Record Type Details


					GH879E9T89

SARS-COV2 B.1.1.7 VARIANT

TARGET ORGANISM->VACCINE ANTIGEN

Comments:

APPEARS TO HAVE COMPARABLE EFFICACY TO NON-VARIANT STRAIN

Amount:


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->VACCINE ANTIGEN

Comments:

From 7 days after second dose to a median time of 2 months.

Qualification:

EFFICACY

Amount:


					BP87QBQ8LZ

TOZINAMERAN EXPRESSED SARS COV2 SPIKE-PROTEIN VACCINE ANTIGEN

EXPRESSED PROTEIN->VECTOR

Amount:


					S8835NH3UH

TOZINAMERAN EXPRESSED SARS COV2 PRE-S-PROTEIN VACCINE ANTIGEN

EXPRESSED PROTEIN->VECTOR

Amount:


					5085ZFP6SJ

TARGET ORGANISM->VACCINE ANTIGEN

Amount:


					YX4JC5JB92

SARS-COV2 P.1 VARIANT

TARGET ORGANISM->VACCINE ANTIGEN

Qualification:

SERUM NEUTRALIZING ABILIT

Amount:

Related Record Type Details


					5085ZFP6SJ

ACTIVE MOIETY

Comments:

Designed to produce neutralizing antibody to the SARS-CoV-2 S glycoprotein. The intention is that such antibodies would protect against SARS-CoV-2 infection and its resulting disease, COVID-19

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
NUCLEOTIDE SUBSTITUTION	[1_1]	5'-TERMINUS			m2-7,3’-OGppp(m1-2’-O)Ap mRNA CAP	VNP8CZY34V
NUCLEOSIDE_SUBSTITUTION		RESIDUE_SPECIFIC			N1-METHYLPSEUDOURIDINE	09RAD4M6WF

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
5'-UTR sequence of the human alpha-globin mRNA with an optimized ʻKozak sequenceʼ	NUCLEIC ACID FEATURE
SARS-COV2 SPIKE CODING SEQUENCE	NUCLEIC ACID FEATURE